## Natasa Gisev

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7397398/natasa-gisev-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55	1,433	18	37
papers	citations	h-index	g-index
60	1,915	4.6 avg, IF	4.83
ext. papers	ext. citations		L-index

#	Paper	IF	Citations
55	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain <i>International Journal of Drug Policy</i> , <b>2022</b> , 105, 103708	5.5	
54	Exposure to childhood trauma increases risk of opioid use disorder among people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 230, 109199	4.9	О
53	Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011-2018. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 221, 108636	4.9	1
52	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , <b>2021</b> , 116, 3139-3152	4.6	3
51	Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 219, 108459	4.9	6
50	Variations in Long-term Opioid Therapy Definitions: A Systematic Review of Observational Studies Using Routinely Collected Data (2000-2019). <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3706-372	2 <b>ð</b> .8	0
49	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3092-3104	3.8	2
48	Patterns and correlates of prescribed and non-prescribed pregabalin use among a sample of people who inject drugs in Australia. <i>Drug and Alcohol Review</i> , <b>2020</b> , 39, 568-574	3.2	1
47	Changes in sales of analgesics to pharmacies after codeine was rescheduled as a prescription only medicine. <i>Medical Journal of Australia</i> , <b>2020</b> , 212, 321-327	4	8
46	Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , <b>2020</b> , 39, 128-134	3.2	3
45	Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 206, 107697	4.9	4
44	Transition to high-dose or strong opioids: a population-based study of people initiating opioids in Australia. <i>Addiction</i> , <b>2020</b> , 115, 1088-1097	4.6	2
43	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Lancet Public Health, The</i> , <b>2019</b> , 4, e334-e342	22.4	13
42	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , <b>2019</b> , 20, 2450-2458	2.8	7
41	Regulatory and other responses to the pharmaceutical opioid problem. <i>Medical Journal of Australia</i> , <b>2019</b> , 210, 6-8.e1	4	15
40	Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review. <i>Research in Social and Administrative Pharmacy</i> , <b>2019</b> , 15, 925-935	2.9	4
39	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet, The</i> , <b>2019</b> , 394, 1668-1684	40	100

## (2016-2019)

38	Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. <i>Drug and Alcohol Dependence</i> , <b>2019</b> , 205, 107533	4.9	15
37	Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia. <i>Drug and Alcohol Review</i> , <b>2019</b> , 38, 690-698	3.2	4
36	Protocol for the Data-Linkage Alcohol Cohort Study (DACS): investigating mortality, morbidity and offending among people with an alcohol-related problem using linked administrative data. <i>BMJ Open</i> , <b>2019</b> , 9, e030605	3	5
35	Trajectories of sickness absence and disability pension before and after opioid initiation for noncancer pain: a 10-year population-based study. <i>Pain</i> , <b>2019</b> , 160, 1224-1233	8	6
34	A population-based study of transdermal fentanyl initiation in Australian clinical practice. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 401-408	2.8	5
33	Prevalence and incidence of prescription opioid analgesic use in Australia. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 202-215	3.8	44
32	Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1267-1278	3.8	34
31	A nationwide study of the extent and factors associated with fentanyl use in Australia. <i>Research in Social and Administrative Pharmacy</i> , <b>2018</b> , 14, 303-308	2.9	5
30	Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims. <i>Pain Medicine</i> , <b>2018</b> , 19, 1170-1183	2.8	4
29	To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 550-555	2.6	25
28	Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. <i>Drug and Alcohol Review</i> , <b>2018</b> , 37 Suppl 1, S203-S205	3.2	21
27	Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. <i>BMJ Open</i> , <b>2018</b> , 8, e025840	3	6
26	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , <b>2018</b> , 5, 464-472	3.9	8
25	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 191, 145-151	4.9	12
24	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 587-591	2.6	28
23	Trends in heroin and pharmaceutical opioid overdose deaths in Australia. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 179, 291-298	4.9	109
22	An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 469-94	2.8	29
21	Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1123-33	3.8	11

20	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 521-38	2.6	50
19	A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 733-7	2.6	192
18	A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. <i>Addiction</i> , <b>2015</b> , 110, 646-55	4.6	44
17	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 1366-76	2.9	5
16	A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. <i>Addiction</i> , <b>2015</b> , 110, 1975-84	4.6	22
15	The POPPY Research Programme protocol: investigating opioid utilisation, costs and patterns of extramedical use in Australia. <i>BMJ Open</i> , <b>2015</b> , 5, e007030	3	8
14	Offending, custody and opioid substitution therapy treatment utilisation among opioid-dependent people in contact with the criminal justice system: comparison of Indigenous and non-Indigenous Australians. <i>BMC Public Health</i> , <b>2014</b> , 14, 920	4.1	7
13	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. <i>BMJ Open</i> , <b>2014</b> , 4, e004666	3	40
12	Imprisonment of opioid-dependent people in New South Wales, Australia, 2000 <b>2</b> 012: a retrospective linkage study. <i>Australian and New Zealand Journal of Public Health</i> , <b>2014</b> , 38, 165-70	2.3	9
11	A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 236-44	2.9	8
10	The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. <i>Addiction</i> , <b>2014</b> , 109, 1306-17	4.6	117
9	A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women. <i>Drug and Alcohol Review</i> , <b>2014</b> , 33, 499-505	3.2	3
8	Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 307-12	1.7	8
7	Interrater agreement and interrater reliability: key concepts, approaches, and applications. <i>Research in Social and Administrative Pharmacy</i> , <b>2013</b> , 9, 330-8	2.9	276
6	Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Addiction</i> , <b>2013</b> , 108, 2152-65	4.6	18
5	Psychotropic drug-regimen changes between community treatment orders. <i>Australasian Psychiatry</i> , <b>2013</b> , 21, 411-2	1.7	
4	Effect of comorbidity on the risk of death associated with antipsychotic use among community-dwelling older adults. <i>International Psychogeriatrics</i> , <b>2012</b> , 24, 1058-64	3.4	8
3	Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study.  Canadian Journal of Psychiatry, 2011, 56, 377-81	4.8	27

## LIST OF PUBLICATIONS

An expert panel assessment of comprehensive medication reviews for clients of community mental health teams. *Social Psychiatry and Psychiatric Epidemiology*, **2010**, 45, 1071-9

4.5 38

Psychiatric Drug Use Among Patients of a Community Mental Health Service. *Disease Management and Health Outcomes*, **2006**, 14, 369-376

10